CSRG investigatory practices for baseline and followup visits.
| Investigation | All SSc Patients Before June 2009, n = 992 (%) | All SSc Patients After June 2009, n = 261 (%) | Comparing All Before 2009 and After June 2009, p | Year 1 Followup and No PAH at Baseline for Echocardiogram Before June 2009, n = 662 (%) | Year 1 Followup and No PAH at Baseline for Echocardiogram After June 2009, n = 106 (%) |
|---|---|---|---|---|---|
| HRCT | 264 (26.6) | 49 (18.8) | 0.0092 | 62 (9.4) | 6 (5.7) |
| Chest radiograph | 762 (76.8) | 173 (66.3) | 0.0005 | 442 (66.8) | 58 (54.7) |
| PFT | 843 (85.0) | 206 (78.9) | 0.0184 | 476 (71.9) | 63 (59.4) |
| ECG | 677 (68.2) | 185 (70.9) | 0.4136 | 406 (61.3) | 61 (57.5) |
| Echocardiogram | 943 (95.1) | 224 (85.8) | < 0.0001 | 582 (87.9) | 63 (59.4) |
CSRG: Canadian Scleroderma Research Group; SSc: systemic sclerosis; PAH: pulmonary arterial hypertension; HRCT: high-resolution computed tomography; PFT: pulmonary function tests; ECG: electrocardiogram.